Although the reprogramming process during
iPSC generation is still wrapped in mystery, the products
offer promise in many areas, such as drug discovery, pathologi-
cal studies, toxicology, the evaluation of secondary drug effects
and regenerative medicine [15]. Here, we outline the current
knowledge and future prospects for induced pluripotency.

(a) Cell transplantation therapy of existing cell banks making available their HLA data of
Since they were first reported in 1998, human ESCs have been stocked cells. In fact, in 2013, the Hyogo Cord blood bank,
strongly expected to be a key to the treatment of intractable dis- one of the non-government organizations in Japan, decided
eases such as Parkinsonâ€™s disease and spinal cord injuries [16]. to provide 10 cord blood cells of HLA-homozygous donors
In 2010, Geron Corporation pressed for the initiation of the for an iPSC stock project organized by Kyoto University.

first-ever clinical trial of ESC-derived oligodendrocyte progeni- Early human iPSC research has coped with problems such
tor cells for the patient with spinal cord injury. Advanced Cell as the integration of viral vectors as a possible risk of tumour-
Technology, another biotechnology company, reported a clini- igenicity [26,27]. Furthermore, the culture media for human

cal trial using ESC-derived retinal pigment epithelium to treat pluripotent stem cells contained animal-derived components


any animal-derived compounds from culture conditions.